Osteoporosis drugs market size was valued at $8 billion in 2018, and is expected to reach $10 billion by 2026, registering a CAGR of 3.9% from 2019 to 2026. Osteoporosis is a medical condition which involves the weakening of the bones. This medical condition is caused due to the overexpression of the parathyroid hormone. Moreover, the weak bones are porous and susceptible to serious fractures. Therefore, osteoporosis has a significant impact on quality of life of patients such as the condition leads to limited mobility. Thus, this medical condition requires treatment which includes the administration of drugs such as bisphosphonates selective estrogen inhibitors modulator (SERM), parathyroid hormone therapy, calcitonin, rank ligand inhibitors and others. Furthermore, these drugs are administered through different routes in the body. For instance, some osteoporosis drugs are administered through the oral route whereas others are administered through the intravenous route.
𝐋𝐢𝐬𝐭 𝐨𝐟 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 :
Amgen Inc., F. Hoffmann-La Roche AG, Radius Health, Inc., Merck & Co. Inc., Novartis International AG (Sandoz), Pfizer Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd
𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://www.alliedmarketresearch.com/request-sample/1491
The osteoporosis drugs market size is studied on the basis of drug class, route of administration, and region to provide a detailed assessment of the market. By drug class, it is segmented into bisphosphonates, selective estrogen inhibitors modulator (SERM), parathyroid hormone therapy, calcitonin, rank ligand inhibitors, and others. Depending on route of administration, it is fragmented into oral, injectable and others. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).
By drug class, the bisphosphonates segment acquired the major share of osteoporosis drugs market in 2018 owing to increase in investment in R&D of advanced novel bisphosphonates drugs by major players. However, rank ligand inhibitors segment is expected to exhibit fastest growth rate during the forecast period owing to the fact that these drugs are used treat bone metastasis by acting as a chemoattractant to bone for tumor cells that express its receptor, RANK. Thus, the inhibition of the RANKL-RANK pathway acts as an ideal treatment for bone metastasis which makes them a preferred choice of drug.
By route of administration, the oral segment acquired for the major share of the osteoporosis drugs market owing to large number of osteoporosis medications which are available as oral drugs in the market. However, the injectable segment is expected to grow at the fastest CAGR during the forecast period owing to factors such as rise in need for drugs which exhibit enhanced bioavailability, and act rapidly.
By region, North America accounted for the major osteoporosis drugs market share in 2018 and is expected to continue this trend, owing to easy availability of osteoporosis drugs. Moreover, surge in the incidence of osteoporosis is another major reason that contributes to the growth of this market. On the other side, Asia-Pacific is estimated to register the fastest growth during the forecast period attributed to the increase in awareness regarding the use of osteoporosis drugs for the treatment of osteoporosis. Moreover, the constantly evolving life science industry drives the growth of the market in developing economies such as India, China, and Malaysia.
𝐅𝐨𝐫 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲 https://www.alliedmarketresearch.com/purchase-enquiry/1491
𝐊𝐄𝐘 𝐅𝐈𝐍𝐃𝐈𝐍𝐆𝐒 𝐎𝐅 𝐓𝐇𝐄 𝐒𝐓𝐔𝐃𝐘
- Bisphosphonates occupied more than one-third share of the global osteoporosis drugs market in 2018.
- The RANK ligand inhibitors segment is anticipated to grow with the highest CAGR throughout the forecast period.
- The oral segment in drug class accounted for more than more than half the share of the market in 2018.
- Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA
𝐎𝐭𝐡𝐞𝐫 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
5933 NE Win Sivers Drive
205, Portland, OR 97220
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060